Biotinylated peptides can be utilized with surface plasmon resonance (SPR) or bio-layer interferometry (BLI) instruments. These devices allow you to measure affinity of antibodies to antigens label-free and in real time with high sensitivity and kinetic resolution. In this application biotinylated peptides are often immobilized on streptavidin coated sensors allowing for oriented immobilization. Oriented immobilization standardizes how many epitopes are presented on the surface of the sensor allowing for accurate measurement of affinity. Another benefit of using biotinylated peptides for antibody affinity determination is that they tend to not strip off the sensor once immobilized on streptavidin sensors during regeneration. This allows you to run multiple antibodies or peptides against the same sensor chip sequentially. These methods can be used for epitope mapping, ranking leads by affinity, and characterizing antibody-antigen interactions.
SPR and BLI assays are commonly performed orthogonal assays used to measure biomolecular interactions that occur during antibody therapeutics discovery and development. Optical biosensors gauge affinity by observing the label-free interaction between an analyte and a bound ligand. Collecting rate kinetic data enables researchers to quantify and characterize molecular interactions. Parameters such as binding strength can be evaluated under a variety of conditions and with multiple antigen formats aiding decision making at various stages of therapeutic development.
SPR-based assays for pathogen detection.1,5
Kinetic binding assays determine association rate constants (kon), dissociation rate constants (koff) and equilibrium dissociation constants (KD). Association rate indicates how fast an antibody will bind to its antigen upon initial encounter. Dissociation rate indicates how long the antibody-antigen complex stays together. The affinity constant describes the overall strength of binding when both rates are at equilibrium. Antibody affinity can be derived from these rates to help predict biological response. Typically, the lower the koff, the longer an antibody will remain bound to its antigen.
Immobilization method is an important consideration when selecting antibodies to develop because it can have a large effect on apparent kinetics. Orientation affects accessibility of epitopes for binding and can limit association if the epitope is oriented towards the sensor surface. If immobilization is random, other effects like increased avidity or occluded epitopes can change the apparent kinetics that you observe. Additionally, in order to select leads, you need consistent and reproducible immobilization between antibodies.
Synthetic peptides afford a limited and defined antigen to aid epitope mapping and specificity determination throughout antibody discovery. Protein antigens can introduce many variables due to the size and complexity of the antigen. By using peptides, affinity can be mapped to determine specific amino acids important for binding. Peptides are especially useful when screening for antibodies to a specific domain, or to characterize cross reactivity to similar peptides. Additionally, peptides are chemically synthesized allowing for a consistent reagent between screening batches.
Peptide-bound assays have intrinsic limitations. Immobilization methods may alter native peptide presentation or orientation, potentially affecting affinity and specificity of binding events. Limitations of peptide bound assays include difficulty in immobilizing peptides onto a surface without disrupting their native conformation and structure. Orientation can be difficult to control and immobilization may result in conformational changes that alter binding kinetics. Surface induced denaturation, signal drift and non-specific adsorption are also contributors to assay readings. The peptides have to be immobilized to the assay surface and maintained in a conformation comparable to the native soluble peptide. Optimization of surface chemistry can minimize these effects by limiting non-specific adsorption and allowing for maintenance of peptide activity.
Table 1 Technical Challenges in Peptide Immobilization for Surface-Based Binding Assays
| Challenge Category | Underlying Mechanism | Experimental Consequence |
| Random orientation | Non-specific surface attachment | Heterogeneous epitope presentation |
| Conformational changes | Surface-induced structural rearrangement | Altered binding kinetics |
| Signal instability | Baseline drift and noise | Reduced measurement precision |
| Regeneration variability | Incomplete surface renewal | Inconsistent results across cycles |
Traditional methods for immobilizing peptides use hydrophobic surfaces to which the peptides can adsorb spontaneously. In these methods there is no control over the orientation of the peptides. Any hydrophobic region of the peptide can contact the surface, and often large regions of the immobilized peptides will contact the surface. When this happens important epitopes of the peptide will be placed directly against the surface, becoming physically blocked from antibody binding. Because random orientation immobilization produces both accessible and inaccessible peptides, the surface becomes a mixture of properly and improperly oriented peptides. This creates mixed responses when conducting kinetics, as it is difficult to determine how many molecules are freely interacting.
Adsorption can cause dramatic changes in conformation of peptides. This effect is especially pronounced when dealing with flexible peptides or peptides that aggregate. When peptides are adsorbed to surfaces they can take on structures that are not observed in solution. Peptides often rearrange themselves upon adsorption to a surface to lower their surface energy. Such restructuring can obscure epitopes or create new epitopes that would not be present on the native protein. This causes inaccurate affinity measurements that do not match solution conditions and can lead to the selection of non-specific antibodies.
Signal drift is often encountered in peptide-based biosensor assays. Signal drift can arise from poor surface conditioning, slow desorption of loosely bound peptide during assay (buffer wash out), and/or nonspecific binding of buffer constituents or analytes. Baseline drift complicates mathematical correction of data and makes it difficult to accurately establish binding endpoints, especially when monitoring dissociation over long time periods where subtle signal changes are important.
Repeated regeneration of the sensor surface to remove residual analyte between measurements will eventually lead to degradation of the immobilized peptide film. Conditions required for dissociation of the complex (acidic/basic or chaotropic conditions) can denature peptides or allow slow-leaching of peptides from the surface. This results in loss of binding capacity, changes to kinetic response, and lower reproducibility between experiments, requiring more frequent replacement of sensors and difficulty with applications needing continuous monitoring over longer periods of time.
Bio-layer interferometry (BLI) and surface plasmon resonance (SPR) technologies utilize biotin-streptavidin binding for immobilization. Immobilization allows for quantitative kinetics of ligand binding by specifically and orientation capture of biotinylated ligands on a sensor surface. Biotinylated ligands are captured by immobilized streptavidin (high affinity towards biotin), allowing for consistent attachment during kinetic cycles. Streptavidin-biotin interactions are so stable that they are irreversible under normal conditions. This allows for reproducible orientation and controlled surface density of immobilized ligands, allowing quantitative antibody-antigen kinetics for any application.
Binding of biotin to streptavidin (SA) is one of the strongest known biologic interactions with sub-femtomolar equilibrium dissociation constant. Hydrogen bonding along with hydrophobic forces and van der Waals forces account for SA's strong affinity to biotin. Since the bond between biotin and streptavidin is so stable, biotinylated ligands will remain bound to SA even after multiple regeneration cycles during kinetic measurements simulating covalent attachment.
General schematic for immunosensor functioning and detection.2,5
Sensor surfaces modified with streptavidin have been prepared by covalently coupling the tetrameric protein to dextran coatings or other chemistries tethered to gold sensor chips or fiber-optic sensors. Up to four streptavidin binding sites are exposed for each surface immobilized protein which allows for oriented immobilization of high density biotinylated ligands. Coupling streptavidin to the sensor surface in this way allows for uniform coating and known surface coverage. Because of the hydrophilic nature of the dextran backbone proteins nonspecifically adsorb to the surface much less frequently. These surfaces have been used to immobilize many biotinylated proteins, peptides, nucleic acids, and carbohydrates.
Constant ligand density across the sensor surface is ideal for rigorous kinetic analysis, high surface coverage leads to mass-transfer limitations and avidity effects that can distort kinetic parameters. Additionally, biotin-streptavidin capture enables controlled immobilization through adjustment of biotinylated analyte concentration and incubation time to reach desired surface densities permitting 1:1 interaction stoichiometry. Strength of the interaction also allows for the capture ligands to withstand long assay times and numerous regenerations with acidic/basic/chaotropic buffers while maintaining a stable baseline for precise affinity measurements.
Immobilization of biotinylated peptides onto the surface also offers many advantages for SPR detection. Peptides can be oriented specifically, and covalently bound to the chip surface allowing for stable immobilization, while eliminating defects caused by randomly adsorbing molecules to the surface. Due to strong affinity between biotin and streptavidin, one can precisely control ligand density and orientation on the surface. Because immobilization is stable and well-defined, observed rates are due to specific interactions between analyte and ligand rather than surface artifacts. These qualities allow determination of high quality affinity constants that can be used for antibody drug discovery by comparing rate constants to gain understanding of which antibody leads to progress further.
The advantage of orienting the peptides to a surface is that they will all point in the same direction. Random immobilization, such as physical adsorption of peptides to a surface, results in molecules that are both accessible to bind to their targets and molecules that have the epitope oriented away from solution, towards the surface. By attaching the peptide to the surface through biotin-streptavidin the biotin can be ligated to either the N-terminus or C-terminus of the peptide (the opposite ends of where the antigen binding site resides). This arrangement guarantees a consistent orientation for all peptides, presenting their epitopes for analyte binding. This ensures that the kinetics will follow a simple 1:1 Langmuir binding model with no complications from hindered accessibility or multivalency. It also means that the affinity constants that are measured are actual thermodynamic values that can be compared between experiments.
Limiting ligand overcrowding with biotin-streptavidin based capture allows more accurate kinetic measurements due to minimized mass transport limitations. In methods where ligands are captured non-specifically, sometimes they will bind so quickly that mass transport will be the rate limiting step, instead of the interaction you are interested in measuring. In other words, the analyte binds so quickly to the surface that it depletes the solution near the sensor surface, distorting true kinetics with mass transport limitations. Using capture techniques that allow for precise dilution of biotinylated peptides you can achieve surface densities low enough to avoid these complications and measure true associations and dissociation rates. Additionally, because of the oriented capture, each molecule on the surface is likely active so lower surface densities can be used compared to creating a randomly adsorbed monolayer.
Binding avidity translates into tight experimental control resulting in high reproducibility between experiments, surfaces, and over time. Surface chemistry effects that plague passive adsorption strategies such as small differences in coating buffers, humidity, temperature, and surface materials have less impact on biotin capture of a ligand due to streptavidin's affinity. With less batch variation in baseline and binding levels experiments taken weeks or months apart, between instruments or operators can be compared with higher confidence. This allows for direct comparisons of kinetic measurements to study processes such as affinity maturation of an antibody response, data generated between laboratories, and for regulatory submissions to provide evidence of assay reliability.
Affinity for streptavidin allows more rigorous regeneration conditions that can be used to completely remove analyte between kinetics measurements. For example, although the bond between biotin and streptavidin is non-covalent, the strength of the interaction allows regeneration conditions that can include low pH buffers, high pH buffers or denaturing agents that can typically be used to disrupt antibody-antigen interactions. This means you can regenerate the same peptide surface multiple times with minimal loss of binding capacity, baseline shift or leaching of ligand for screening multiple clones of antibodies or antibody dilutions against the same surface-immobilized ligand. This conserves both antibodies and antigens while removing the variability caused by degradation of surfaces over multiple experiments.
Peptides modified with biotin also offer unique advantages in BLI assays. Biotinylated peptides can be immobilized quickly and in an orientation-specific manner onto streptavidin biosensors. Unlike other immobilization methods that require physical adsorption, biosensors can be plunged directly into solutions containing biotinylated peptides. This allows one to bypass complex fluidics needed for other biosensor assays. Consistent with oriented immobilization, all epitopes remain accessible during association and dissociation phases of an experiment. And because of the strong affinity between biotin and streptavidin, there will be little baseline drift. These features allow kinetic analysis to be performed efficiently, which is useful for applications such as screening antibody libraries.
Binding between biotin and streptavidin allows very quick immobilization of the ligand onto the sensor chip. Typically immobilization can be done in minutes instead of hours which are often needed for passive adsorption immobilization strategies. This becomes very convenient if large numbers of sensors chips need to be prepared, for example in high throughput applications. Another benefit is that due to the specificity of binding only biotinylated peptides will bind to the sensor chip surface. This is in contrast to some other chemistries where unspecific binding of proteins may occur, resulting in shorter washing and blocking times before introducing the analyte.
Due to the very stable biotin-streptavidin interaction the biosensor surface-bound ligand does not dissociate appreciably during association or dissociation measurement periods. With weaker non-covalent linkages between ligand and surface the bound ligand slowly leaks away during buffer flow and over the course of association and dissociation measurement periods. Because surface density remains essentially constant during an experiment using streptavidin surfaces one does not observe baseline drift due to dissociation of ligand from the sensor surface. As a result signal changes that occur during biosensor-analyte interactions can be attributed to the binding/unbinding of analyte to/from the ligand rather than loss of ligand from the sensor surface compromising the integrity of the measurement.
The directional immobilization and dense labeling possible with streptavidin-biotin interactions also improves sensitivity when detecting antibodies with low affinity. The tetrameric structure allows for several linkages to withstand harsh washing procedures that would normally eliminate these weak immune complexes. In addition, because the antibody is immobilized in a consistent manner, epitopes will not be hindered allowing for optimal interaction with low affinity antibodies that are typically used at limiting concentrations, increasing the range of affinities that can be detected compared to physically adsorbed preparations.
The dip and read instrumentation utilized for bio-layer interferometry allows straightforward automation with the help of strong biotin-streptavidin interactions. Bio-Layer interferometry assays may be conducted in conventional microplates. Thus robots can perform assays on hundreds to thousands of biosensors with little hands-on time. Fast association rates and immobilization chemistry allow high-throughput screening of libraries of antibodies against biotinylated peptides. Libraries can easily be screened that would take unreasonable lengths of time with less throughput techniques. This allows for faster discovery of therapeutic antibodies without sacrificing the quality of information gained for affinity ranking and epitope binning.
Designing peptides labeled with biotin for kinetic experiments can be done rationally. Factors like positioning of biotin tags away from functionally important epitopes, integration of spacer chemistries, limiting immobilization surface density, and ensuring solubility in aqueous buffers can all contribute to measuring true binding parameters vs. artifactually affected results. These factors attempt to address maintaining tethered surfaces while not affecting the inherent association and dissociation rate constants. For this reason, peptides are sometimes used to ensure correct orientation and kinetics similar to that in solution.
Table 2 Design Parameters for Biotinylated Peptides in Kinetic Analysis
| Design Element | Strategic Consideration | Functional Impact |
| Biotinylation site | Terminal placement distal from binding determinants | Preserved epitope accessibility and native binding kinetics |
| Spacer arm | Ahx or PEG linkers of defined length | Reduced steric interference from sensor surface |
| Ligand density | Controlled surface concentration | Minimized mass transport artifacts and avidity effects |
| Solubility | Hydrophilic sequence design and buffer optimization | Prevented aggregation and non-specific surface interactions |
Chemical attachment of biotin should be engineered to a terminus of the peptide or appended via a linker so that chemical conjugation does not affect antibody recognition. N- or C-terminal specific attachment of biotin, sufficiently separated from the antigenic epitope, is ideal as chemical attachment does not sterically hinder any binding residues nor affect how the peptide folds. This facilitates attachment to a streptavidin surface and ensures antibodies interact specifically with the peptide while not compromising on kinetics due to steric limitations.
Spacer arms between biotin and peptides are important for optimizing rotation and accessibility of immobilized antigens. Spacer arms can be based on aminohexanoic acid, which is shorter and more rigid; this can be used for smaller peptides. Polyethylene glycol-based spacers are longer and more flexible. Spacer arms distance the peptide further away from the sensor surface, minimizing steric hindrance from contact with the streptavidin layer. This allows for antibodies to bind to their epitope with kinetics similar to those seen in solution.
Kinetic parameters are highly dependent on controlled ligand density. Dense packing of ligands will enhance mass transport effects and avidity effects that can alter the apparent affinity. Ligand density can be controlled by altering the concentration of biotinylated peptide used to incubate with the sensor surface during the loading step. Surface densities should be low enough that the kinetics are measured under diffusion-controlled conditions (minimal rebinding effects during dissociation and no avidity effects). With careful control of surface density, true association and dissociation rate constants can be determined.
Solubility in water is another consideration for designing peptides for biosensor applications. Peptides with significant hydrophobicity may aggregate in aqueous solution, which causes unreliable biosensor results. Aggregation leads to non-specific binding and unclear kinetics. Often times, adding charged or polar residues to the N- or C-terminus, or within a linker region of a peptide will increase its water solubility. This has minimal effects on the antigenicity of the peptide. If the peptide of interest is highly hydrophobic, it may be necessary to run your biosensor in a buffer that contains organic solvents or detergent to break up aggregates of the peptide. Aggregation can hide true antibody binding or cause false signals due to non-specific binding to the sensor surface.
For experimental comparison to immobilizing ligands directly onto a surface (physically adsorbing or covalently attaching directly to an amine coupling chemistry), immobilizing biotinylated peptides can have several advantages and disadvantages. Direct immobilization can cause random orientation of ligands on a surface and some ligands may not expose the active binding site. This orientation can create variability in data compared to consistently oriented immobilization of biotinylated ligands using streptavidin. With proper surface density control immobilizing through streptavidin-biotin can lead to more reproducible kinetics, less variation in signal over long runs, and improved surface lifetime during regeneration.
Kinetic improvements are also gained with biotinylated peptides compared to direct immobilization due to the oriented immobilization strategy allowing for presentation of the ligand in a manner more closely related to the ideal scenario of a one-to-one interaction that is derived with assumptions of random orientation. With site-specific immobilization all of the ligand molecules are displayed in accessible orientations, as opposed to creating a heterogeneous mixture of some molecules that may have buried ligands from contact with the sensor surface or are forced into unnatural structures. Having a consistent ratio of accessible ligands allows for kinetics to be measured that are not skewed by improperly displayed molecules. Because biotinylation sites can be varied the density of ligand on the sensor surface can easily be controlled which avoids problems with mass transport limitations and rebinding that plague very dense surfaces from direct immobilization allowing for true thermodynamic parameters to be determined.
Kinetic analysis and the regeneration required for multiple cycles of analysis are facilitated by the stability of the biotin/streptavidin interaction. Conventional surfaces that rely on immobilized proteins can suffer conformational changes, chemical degradation or loss of binding activity when exposed to the acidic/basic/randomicular regenerants required to disrupt binding events. This is not the case for biotinylated peptides since the bound peptide does not wash off under conditions that will displace the analyte. You can regenerate the same ligand surface hundreds of times which enables multiple antibody clones or serial dilutions of an analyte to be tested without changes to the surface characteristics.
Signal ranges achieved when using biotinylated peptides as sensor surfaces are easily repeatable over many cycles of binding and regeneration. Baseline and binding range stability over long periods of time are easily achievable with these surfaces. With directly immobilized ligands, these surfaces may experience changes in surface or ligand integrity over time causing problems such as decreasing maximum response levels, changing kinetics, or drifting baselines from one cycle to the next. Because each regeneration cycle with streptavidin begins with essentially the same surface, data taken years apart can be directly compared and statistical significance can be achieved over many repeated measurements.
Increasing throughput of peptide synthesis from benchtop scales to commercial quantities requires optimization of the synthesis process to sustain analytical performance over long duration screens. Decisions need to be made around production processes, quality assurance testing and logistics to adequately support the structural fidelity needed for proper protein interaction. Many pitfalls may be encountered when scaling up production such as losing analytical sensitivity or introducing variability into your batches. Tradeoffs include: validating manufacturing processes to confirm peptide integrity, establishing robust synthetic methods that can consistently reproduce batches and scaling-up the production capacity to support longer screens.
High-performance liquid chromatography with mass spectrometry characterization is one way that peptide integrity can be checked before use in binding assays. Reverse-phase high-performance liquid chromatography should separate the desired sequence from other synthetic byproducts such as deletion peptides/truncations or missed deprotection that may be present and would likely compete for binding with the antibody of interest. Mass spectrometry should verify the correct molecular weight and sequence by providing the accurate mass of the intact peptide and by fragmentation of the molecule. Sequence verification can also be performed with liquid chromatography-tandem mass spectrometry by analyzing the fragment ions that are produced. The combination of these techniques can confirm that the material used is the correct sequence.
Batch-to-batch consistency is an important issue when large numbers of peptides are required for screening. Differences in synthesis yield, recovery through purification steps, handling/storage conditions etc., may change peptide characteristics so that binding is not reproduced consistently. Following standard procedures for solid phase synthesis, using in-process controls during synthesis and careful record keeping of process parameters will ensure consistency between batches of peptides. This will be important if multiple rounds of screening are performed as variation in antigen could mask the actual antibody binding pattern, make subtle differences in affinity between clones difficult to detect or require re-validation of assay conditions.
Once optimized on a smaller scale, synthesis processes are typically upscaled for screening applications. Large-scale synthesis needs to adapt process workflows to increased quantity while still sustaining robust quality attributes. Solid-phase systems need to scale resin loadings and reaction vessel size without affecting coupling efficiency or creating synthetic defects. Purification methods also need to be adjusted to account for increased volume of crude peptide. Forecasting dependable supply of raw materials, along with available equipment capacity and quality control analysis capacity will help ensure continued availability for long campaigns. These scaled processes allow for the medicinal chemistry iterative process within antibody discovery. Several rounds of screening against the same antigen preparation are often required to identify ideal drug candidates.
Accurate kinetic measurements in SPR and BLI assays depend heavily on the quality, purity, and structural integrity of the immobilized ligand. When working with biotinylated peptides, partnering with an experienced peptide manufacturer can significantly improve assay reliability and data consistency. A qualified supplier should provide guidance on site-specific biotinylation to ensure that the modification does not interfere with the antibody-binding region or critical interaction motifs. Proper control of labeling position helps maintain native binding behavior and supports accurate determination of kinetic parameters such as association (Kon), dissociation (Koff), and equilibrium affinity (KD).
In addition to conjugation strategy, analytical validation is essential. Peptides should be purified using high-performance liquid chromatography (HPLC) and verified by liquid chromatography-mass spectrometry (LC–MS) to confirm molecular identity and successful biotin incorporation. Consistent purity specifications and batch-to-batch reproducibility are particularly important in SPR and BLI workflows, where small variations in ligand density or structural integrity can affect baseline stability and kinetic accuracy.
Scalable and controlled manufacturing processes also support long-term assay development programs. Standardized synthesis protocols, documented production workflows, and traceable batch records help ensure consistent surface capture behavior across multiple sensor chips or biosensor lots. By collaborating with a technically competent peptide manufacturer, research teams can reduce variability, improve surface stability, and enhance confidence in kinetic data generated from SPR and BLI binding assays.
If you are planning kinetic binding studies and require analytically validated biotinylated peptides optimized for SPR or BLI platforms, contact our team to discuss your assay requirements or request a customized quotation for your project.
When biotin is introduced through site-specific labeling away from the binding interface, it generally does not alter intrinsic affinity. Proper design ensures that kinetic parameters (Kon, Koff, KD) reflect true molecular interactions rather than surface artifacts.
Directional immobilization via biotin–streptavidin capture promotes uniform ligand orientation, improving epitope accessibility and reducing variability. This helps generate more reliable association and dissociation curves in both SPR and BLI systems.
Spacer length depends on peptide size and assay configuration. Linkers such as aminohexanoic acid (Ahx) or PEG are commonly used to reduce steric hindrance and improve binding accessibility. Optimization may be required to balance flexibility and surface stability.
Ligand density is controlled by adjusting peptide concentration during capture and monitoring response units (SPR) or binding signal (BLI). Lower to moderate densities are often preferred to minimize mass transport effects and rebinding artifacts.
In many cases, the strong biotin–streptavidin interaction provides stable surface attachment across regeneration cycles. However, regeneration conditions should be validated to ensure they do not disrupt peptide integrity or compromise binding performance.
References
